Gilgamesh links psychedelic to 94% remission rate in midphase depression trial
Almost all the patients with depression who received Gilgamesh Pharmaceuticals’ psychedelic drug candidate went into remission, furthering the biotech’s attempt to follow the trail blazed by Johnson & Johnson.
Almost all the patients with depression who received Gilgamesh Pharmaceuticals’ psychedelic drug candidate went into remission, furthering the biotech’s attempt to follow the trail blazed by Johnson & Johnson.
